Solid Tumors Clinical Trial
Official title:
Phase Ib Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors
Verified date | February 2018 |
Source | Fondazione Michelangelo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
PI3K signaling is a hallmark of many cancers. Subsets of cancers become dependent on PI3K
pathway signaling as a result of mutations of the PIK3CA gene itself or of regulators of PI3K
(e.g. PTEN, HER2). As a consequence, pathway mutated tumors are particularly sensitive
towards PI3K-pathway inhibition. BKM120 is a potent and highly specific oral pan-class I
PI3K-inhibitor.
The study FM-11-F01b is a phase Ib single institution study using the combination of BKM120
and cisplatin or carboplatin in patient with pathologically confirmed recurrent or metastatic
advanced solid tumor, for which treatment with a platinum agent is indicated (preferentially
head and neck, NSCLC, ovary, endometrial).
The primary objective of the study is to define the phase II recommended dose of daily oral
BKM120 and cisplatin (Group 1) or carboplatin (Group 2), given intravenously (IV) on day 1
every 3 weeks.
Status | Completed |
Enrollment | 34 |
Est. completion date | December 31, 2017 |
Est. primary completion date | June 9, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Patient has provided a signed Informed Consent Form (ICF) obtained prior to any screening procedure; - Patient is = 18 years at the day of consenting to the study - Patient has an ECOG performance status = 1 - Pathologically confirmed recurrent or metastatic advanced solid tumor, for which treatment with a platinum agent is indicated - Life expectancy = 6 months - Patient has adequate bone marrow and organ function - Patient must be able to swallow and retain oral medication - Patient may have received more than 1 prior cytotoxic chemotherapy regimens for recurrent or metastatic disease - Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential - Patients may receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture - Patients must be disease-free of other prior invasive cancers for > 5 year - Patients must complete all screening assessments as outlined in the protocol Exclusion Criteria: - Patient has received previous treatment with PI3K and/or mTOR inhibitors - Patient has received chemotherapy or targeted anticancer therapy = 4 weeks prior to starting study drug or has not recovered from side effects of such therapy - Patient has symptomatic CNS metastases (Patients with controlled and asymptomatic CNS metastases may participate in this trial) - Patient has any of the below mood disorders as judged by the Investigator or a Psychiatrist, or meets the cut-off score of = 10 in the PHQ-9 or a cut-off of = 15 in the GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9) - Patient is concurrently using other approved or investigational antineoplastic agent - Patient has received wide field radiotherapy = 4 weeks prior to starting study drug - Patient has had major surgery within 2 weeks days prior to starting study drug; - Patients with diabetes mellitus or steroid-induced diabetes mellitus or known intolerance to glucides or fasting glucose > 120 mg/dL or HbA1c > 8 % - Patient has important cardiac disease - LVEF < 50%; NYHA Class III or IV - QTc > 480 msec; Congenital long QT syndrome - Clinically significant resting bradycardia - Complete left bundle branch block; Right bundle branch block + left anterior hemiblock - Patient has impairment of GI function or GI disease - Patient receiving chronic treatment with steroids or another immunosuppressive agent. - Patient has other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate his/her participation in the clinical study (e.g.,chronic pancreatitis, active or chronic liver disease, renal disease etc.) - Patient has diarrhea = 2 CTCAE grade 2 - Preexisting peripheral neuropathy > grade 1 - Patient has been treated with any hematopoietic colony-stimulating growth factors = 2 weeks prior to starting study drug - Prior hypersensitivity reaction to carboplatin or cisplatin - Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or patient has a history of non-compliance to medical regimen - Patient is currently being treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. - Patient has a known history of HIV (infection; 21. Patient is a pregnant or nursing (lactating) woman - Patient is a man or woman of childbearing potential unwilling to use a double barrier method for birth control throughout the trial |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale San Raffaele | Milano | MI |
Lead Sponsor | Collaborator |
---|---|
Fondazione Michelangelo |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with dose limiting toxicities in each of the study dose levels | Determination of phase II recommended dose of daily oral BKM120 and cisplatin (Group 1) or carboplatin (Group 2), based upon drug related Dose Limiting Toxicities as described in the protocol at the end of Cycle 1 (each cycle is 22 days) | 36 months | |
Secondary | Response rate | Defined as the percentage of complete or partial responders assessed by RECIST criteria (v1.1) | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |